Annexon To Present New Phase 2 ARCHER Data For ANX007 In Dry AMD Patients With Less Advanced GA At The American Academy Of Ophthalmology 2024 Meeting

Benzinga · 10/15 12:18

ANX007 Demonstrated Significant Vision Protection in Standard and Low Light Conditions and Significant Photoreceptor Preservation in the Fovea Region Critical for Visual Acuity

 

Phase 3 Data from Ongoing ARCHER II Pivotal Program Expected Second Half 2026

BRISBANE, Calif., Oct. 15, 2024 (GLOBE NEWSWIRE) -- Annexon, Inc. (NASDAQ:ANNX), a biopharmaceutical company focused on upstream C1q to advance therapies for neuroinflammatory diseases of the body, brain and eye, today announced the Company will present new analyses of ANX007 from the completed Phase 2 ARCHER trial in geographic atrophy (GA) at the American Academy of Ophthalmology (AAO) 2024 annual meeting being held October 18-21 in Chicago, Illinois, and at the Eyecelerator conference at AAO being held Thursday, October 17, 2024. ANX007 is a first-in-kind, non-pegylated antigen-binding fragment (Fab) designed to block C1q locally in the eye with an intravitreal formulation.